血管平滑肌芳基乙醯胺脫乙醯基酶可預防動脈粥樣硬化
作者:
小柯機器人發布時間:2020/5/16 11:52:06
美國哈佛醫學院Chad A. Cowan、Takafumi Toyohara等研究人員合作利用病人來源的誘導多能幹細胞發現,血管平滑肌芳基乙醯胺脫乙醯基酶可預防動脈粥樣硬化。相關論文於2020年5月14日在線發表在《細胞—幹細胞》雜誌上。
研究人員表示,儘管每個患者對心血管疾病(CVD)的敏感性均不同,但是尚不清楚為何某些2型糖尿病(T2DM)患者發展為CVD而其他患者卻沒有。
使用T2DM患者來源的人誘導多能幹細胞(hiPSC),研究人員發現在患有CVD的患者中,血管平滑肌細胞(VSMC)中一種酯酶——芳基乙醯胺脫乙醯基酶(AADAC)的表達明顯升高。研究人員在人類原代VSMC和與hiPSC分化的VSMC中過表達了這種酯酶,並觀察到脂滴的數量顯著減少。
進一步的代謝組學分析表明,脂質的存儲量顯著減少、膜磷脂增加,這表明脂質生物裝配的甘迺迪途徑(Kennedy pathway)發生了變化。在過表達AADAC的VSMC中,細胞遷移和增殖也顯著降低。此外,在載脂蛋白E(Apoe)敲除小鼠中過表達VSMC特異性Aadac能夠改善動脈粥樣硬化病變。這些發現表明,VSMC中較高的AADAC表達可保護T2DM患者免於CVD。
附:英文原文
Title: Patient hiPSCs Identify Vascular Smooth Muscle Arylacetamide Deacetylase as Protective against Atherosclerosis
Author: Takafumi Toyohara, Filip Roudnicky, Mary H.C. Florido, Toshiaki Nakano, Haojie Yu, Shunsuke Katsuki, Minjin Lee, Meissner Torsten, Max Friesen, Lance S. Davidow, Leon Ptaszek, Takaaki Abe, Lee L. Rubin, Alexandre C. Pereira, Masanori Aikawa, Chad A. Cowan
Issue&Volume: 2020-05-14
Abstract: Although susceptibility to cardiovascular disease (CVD) is different for every patient,why some patients with type 2 diabetes mellitus (T2DM) develop CVD while others areprotected has not yet been clarified. Using T2DM-patient-derived human induced pluripotentstem cells (hiPSCs), we found that in patients protected from CVD, there was significantlyelevated expression of an esterase, arylacetamide deacetylase (AADAC), in vascularsmooth muscle cells (VSMCs). We overexpressed this esterase in human primary VSMCsand VSMCs differentiated from hiPSCs and observed that the number of lipid dropletswas significantly diminished. Further metabolomic analyses revealed a marked reductionin storage lipids and an increase in membrane phospholipids, suggesting changes inthe Kennedy pathway of lipid bioassembly. Cell migration and proliferation were alsosignificantly decreased in AADAC-overexpressing VSMCs. Moreover, apolipoprotein E(Apoe)-knockout mice overexpressing VSMC-specific Aadac showed amelioration of atheroscleroticlesions. Our findings suggest that higher AADAC expression in VSMCs protects T2DMpatients from CVD.
DOI: 10.1016/j.stem.2020.04.018
Source: https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(20)30157-0